Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: aknahow who wrote (9839)	5/7/1999 11:25:00 AM
From: Arthur Radley	Read Replies (2) \| Respond to of 17367

I've been away for a few days and haven't had the opportunity to read all the messages here on SI. Just had a chance to briefly revenue the annual report. Maybe this has been posted and discussed, but could someone clarify for me what is written on page 15 of the annual report....."Why NEUPREX? NEUPREX kills gram-negative bacteria like N.meningitidis." My point is that there are no qualifiers for this statement that NEUPREX "kills" bacteria. Is this a hint as to what they know about the trials? Often biotechs freely use the wording of "potentially" a drug will do such and such.